Detecting the MET Exon 14 Skipping Mutations in NSCLC

January 16, 2020
Willemina R. Geurts-Giele, PhD

Willemina R. Geurts-Giele, PhD, discusses 2 approaches used to detect the MET exon 14 skipping mutation in patients with non-small cell lung cancer.

Willemina R. Geurts-Giele, PhD, University Medical Center, Rotterdam, The Netherlands, discusses 2 approaches used to detect theMETexon 14 skipping mutation in patients with non-small cell lung cancer (NSCLC).

Clinicians can use either RNA or DNA, Geurts-Giele says. With RNA, a simple polymerase chain reaction is used because it is the same event, which is very easy. However, the downside is that patients with NSCLC do not have as much material.

DNA analyses are routinely done in pathology departments, while the use of RNA is still evolving in labs. In her analysis, Guerts-Giele used DNA analysis to determine theMETexon 14 skipping mutation because they regularly run the analysis on their patient’s materials.